Shots:

• The acquisition will bolster UCB’s pipeline program- capabilities- and platforms in the gene therapy space. The Handl Therapeutics will continue to be based in Leuven- Belgium while working closely with UCB’s international research teams
• In addition- the UCB collaborated with Lacerta to focus on CNS diseases- under which Lacera will lead research- preclinical activities- and the early manufacturing process development- while UCB will complete IND-enabling studies- manufacturing- and clinical development
• The collaboration will allow UCB to access Lacerta’s expertise in AAV-based CNS targeted gene therapies- fortifying UCB's ability to produce effective treatments for neurodegenerative diseases

­  Ref: PRNewswire | Image: The Pharma Letter